Trial · NCT07551778
Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors
NCT07551778, Phase 1, Phase 2, Not yet recruiting, BOE Technology Group Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors. Trials, record NCT07551778. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07551778
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors
- NCT number
- NCT07551778
- Status
- Not yet recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 42 participants, estimated
- Lead sponsor
- BOE Technology Group Co., Ltd.
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer), Colorectal Cancer, Advanced Solid Tumors, Advanced Hepatocellular Carcinoma (HCC), GC/GEJC
- Interventions
NK Cells, NK cells + PD-(L)1 inhibitor + pemetrexed as first-line maintenance therapy, NK cells + cetuximab/bevacizumab + capecitabine as first-line maintenance therapy, NK cells + PD-(L)1 inhibitor + VEGF inhibitor as first-line maintenance therapy, NK cells + PD-(L)1 inhibitor + capecitabine or S-1 as first-line maintenance therapy
- First posted
- 2026-04-27
- Last updated
- 2026-08-26
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Dose-Limiting Toxicity (DLT) | During the first treatment cycle (21 days for Cohorts 1&3, 14 days for Cohort 2) | Incidence of DLT defined as: Grade 4-5 CRS or ICANS related to NK cells; Grade 3 CRS/ICANS not resolving to ≤Grade 2 within 7 days; Grade ≥3 non-hematologic toxicity not resolving to Grade 2 or baseline; Grade 4 hematologic toxicity not resolving to Grade 2 or baseline within DLT observation period |
| Primary | Adverse Events (AE) | From first dose through 30 days after last dose | Incidence and severity of treatment-emergent adverse events assessed by NCI-CTCAE v5.0 |
| Secondary | Progression-Free Survival (PFS) | From enrollment until disease progression or death, up to 2 years | Progression-Free Survival (PFS) |
| Secondary | Objective Response Rate (ORR) | From enrollment until disease progression or death, up to 2 years | Proportion of patients achieving complete response (CR) or partial response (PR) per RECIST 1.1 |
| Secondary | Duration of Response (DOR) | up to 24 months | From date of first documented response (CR or PR) until date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months |
| Secondary | Disease Control Rate (DCR) | Up to 2 years | Proportion of patients with CR, PR, or stable disease (SD) |
| Secondary | Circulating Tumor DNA (ctDNA) Changes | Baseline, every 6 weeks during treatment (up to approximately 12 months), and at end of treatment, up to 12 months | Changes in peripheral blood ctDNA levels |
| Secondary | Quality of Life EORTC QLQ-C30 | Baseline, every 6 weeks during treatment, and at end of treatment, up to 24 months | Changes in EORTC QLQ-C30 scores |
| Secondary | Quality of Life EORTC EQ-5D-5L | Baseline, every 6 weeks during treatment, and at end of treatment,up to 24 months | Changes in EQ-5D-5L utility index score |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07551778
GET https://conductscience.org/api/trials/v1/NCT07551778/registered